ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-CD7 CAR T Cells PA3-17

Its studies are mostly in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Scleroderma, Systemic · Lymphoma, led by PersonGen BioTherapeutics (Suzhou).

Drug pageAutologous Anti-CD7 CAR T Cells PA3-17: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 16, 20256 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PersonGen BioTherapeutics (Suzhou)63 open or runningphase 2since Sep 16, 2025Jul 14, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2020First study: phase 1 study in LymphomaFirst studyNCT04480788 · 9 enrolled · China
  2. Mar 3, 2021No phase study in Precursor T-Cell Lymphoblastic Leukemia-LymphomaNCT04785833 · 20 enrolled · China
  3. Dec 24, 2021Phase 1 study in CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesNCT05170568 · 22 enrolled · China
  4. Feb 27, 2025No phase study in Systemic Sclerosis - 2013 ACR/EULAR Classification CriteriaNCT06871644 · 18 planned · China
  5. Sep 16, 2025Phase 2 study in CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaNCT07188610 · 100 planned · China
  6. May 28, 2026Phase 1 study in CD7+ T-ALL/LBLNCT07623681 · 12 planned · China

TargetBeta

CD7 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, ”NCIt, by rule

Other programs on CD7

ProgramCompanyFurthest phaseStudies
Anti-CD7 CAR-T Cells RD13-02rulenanjing-bioheng-biotech-co-ltdearly phase 11
UTAA07rulePersonGen BioTherapeutics (Suzhou)early phase 11

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623681CD7+ T-ALL/LBL · China1Not yet recruitingJun 30, 202612
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma · China2RecruitingOct 1, 2026100
NCT06871644Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria · China–Not yet recruitingMar 31, 202618
NCT05170568CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · China1UNKNOWNDec 1, 202222
NCT04785833Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China–UNKNOWNApr 30, 202220
NCT04480788Lymphoma · China1UNKNOWNAug 1, 20229

How it is read

Names in the registry

  • “T cell injection targeting CD7 chimeric antigen receptor”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.